InsiderSignal.AI

InsiderSignal.ai

ALMS - Alumis Inc.

Insider Purchase by Tananbaum James B. (Dir, 10%)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

3 months ago, Tananbaum James B., serving as Dir, 10% owner at Alumis Inc. (ALMS), purchased 507,874 shares at $6.09 per share, for a total transaction value of $3,094,725.00. Following this transaction, Tananbaum James B. now holds 15,705,828 shares of ALMS.

This purchase represents a 3.00% increase in Tananbaum James B.'s stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, November 17, 2025 and publicly disclosed via SEC Form 4 filing on Wednesday, November 19, 2025, 2 days after the trade was made.

Alumis Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Tananbaum James B.

Dir, 10%

James B. Tananbaum, M.D., M.B.A. is an independent Class II Director at Alumis Inc. (ALMS), serving since January 2021 and as a member of the Compensation Committee.[[1]](https://fintool.com/app/research/companies/ALMS/people/james-tananbaum) Age 62, he holds significant ownership (~15.8%) through Foresite Capital-affiliated funds, reflecting his recent insider trading activity as Director, 10%.[[1]](https://fintool.com/app/research/companies/ALMS/people/james-tananbaum) Tananbaum is the founder, President, and CEO of Foresite Capital Management, a U.S.-focused healthcare investment firm established in 2011 with ~$3.5B in assets under management, and co-founder of Foresite Labs.[[2]](https://foresitelabs.com/about/jim-tananbaum-md/)[[4]](https://www.foresitecapital.com/people/jim-tananbaum/) Tananbaum's career highlights include co-founding GelTex Pharmaceuticals (1991, acquired by Sanofi-Genzyme for $1.6B), serving as founding CEO of Theravance, Inc. (1997, spun into Innoviva and Theravance Biopharma with combined market cap exceeding $4B), and co-founding/managing director roles at Prospect Venture Partners (2000–2010).[[1]](https://fintool.com/app/research/companies/ALMS/people/james-tananbaum)[[2]](https://foresitelabs.com/about/jim-tananbaum-md/)[[4]](https://www.foresitecapital.com/people/jim-tananbaum/) Earlier, he was a partner at Sierra Ventures and senior product manager at Merck.[[5]](http://web.mit.edu/hst/35_dev/profiles/tananbaum.html) He holds an M.D. and M.B.A. from Harvard, and B.S. in Applied Math and B.S.E.E. from Yale.[[1]](https://fintool.com/app/research/companies/ALMS/people/james-tananbaum)

View full insider profile →

Trade Price

$6.09

Quantity

507,874

Total Value

$3,094,725.00

Shares Owned

15,705,828

Trade Date

Monday, November 17, 2025

97 days ago

SEC Filing Date

Wednesday, November 19, 2025

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Alumis Inc.

Company Overview

No company information available
View news mentioning ALMS

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/1286554

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime